RU2632445C2 - Композиции и способы доставки терапевтических средств - Google Patents

Композиции и способы доставки терапевтических средств Download PDF

Info

Publication number
RU2632445C2
RU2632445C2 RU2013122656A RU2013122656A RU2632445C2 RU 2632445 C2 RU2632445 C2 RU 2632445C2 RU 2013122656 A RU2013122656 A RU 2013122656A RU 2013122656 A RU2013122656 A RU 2013122656A RU 2632445 C2 RU2632445 C2 RU 2632445C2
Authority
RU
Russia
Prior art keywords
rtv
drug
nanoparticle
atv
nanoart
Prior art date
Application number
RU2013122656A
Other languages
English (en)
Russian (ru)
Other versions
RU2013122656A (ru
Inventor
Говард И. ГЕНДЕЛЬМАН
Александр В. КАБАНОВ
Синь-мин ЛЮ
Original Assignee
Боард Оф Реджентс Оф Де Юниверсити Оф Небраска
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Боард Оф Реджентс Оф Де Юниверсити Оф Небраска filed Critical Боард Оф Реджентс Оф Де Юниверсити Оф Небраска
Publication of RU2013122656A publication Critical patent/RU2013122656A/ru
Application granted granted Critical
Publication of RU2632445C2 publication Critical patent/RU2632445C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2013122656A 2010-11-02 2011-11-02 Композиции и способы доставки терапевтических средств RU2632445C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40937210P 2010-11-02 2010-11-02
US61/409,372 2010-11-02
US201161526976P 2011-08-24 2011-08-24
US61/526,976 2011-08-24
PCT/US2011/058929 WO2012061480A2 (en) 2010-11-02 2011-11-02 Compositions and methods for the delivery of therapeutics

Publications (2)

Publication Number Publication Date
RU2013122656A RU2013122656A (ru) 2014-12-10
RU2632445C2 true RU2632445C2 (ru) 2017-10-04

Family

ID=46025083

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013122656A RU2632445C2 (ru) 2010-11-02 2011-11-02 Композиции и способы доставки терапевтических средств

Country Status (8)

Country Link
US (1) US20130236553A1 (https=)
EP (1) EP2635260A4 (https=)
JP (1) JP2013542945A (https=)
AU (1) AU2011323458B2 (https=)
CA (1) CA2816123A1 (https=)
MX (1) MX2013004981A (https=)
RU (1) RU2632445C2 (https=)
WO (1) WO2012061480A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
ITRM20120350A1 (it) * 2012-07-19 2014-01-20 Univ Degli Studi Milano Nanocostrutti con attività farmacologica.
EP2925319B1 (en) * 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
US20160136105A1 (en) * 2013-04-11 2016-05-19 Board Of Regents Of The University Of Nebraska Compositions and Methods for the Delivery of Therapeutics
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20170165271A1 (en) * 2014-02-24 2017-06-15 The Board Of Regents Of The University Of Nebraska Compositions and Methods for the Delivery of Therapeutics
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20160346221A1 (en) * 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
EP3190176A1 (en) 2016-01-11 2017-07-12 IMBA-Institut für Molekulare Biotechnologie GmbH Method for tissue culture development on scaffold and differentiated tissue culture
US9872859B2 (en) * 2016-02-20 2018-01-23 The Florida International University Board Of Trustees Materials and methods for targeting therapeutic compositions to gut-associated lymphoid tissue (GALT)
EP4299133A3 (en) 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
EP3737359A4 (en) 2018-01-12 2021-11-03 Board of Regents of the University of Nebraska ANTIVIRAL MEDICINES AND FORMULATIONS OF THEM
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
ES2970251T3 (es) * 2018-10-22 2024-05-27 Univ Nebraska Profármacos antivirales y nanoformulaciones de los mismos
WO2020112931A1 (en) 2018-11-29 2020-06-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20050048002A1 (en) * 2003-06-24 2005-03-03 Barrett Rabinow Method for delivering drugs to the brain
RU2008129083A (ru) * 2006-04-24 2010-01-20 Нм Тек Лтд. Наноматериалз Энд Микродевайсиз Текнолоджи (Gb) Функциональные наноматериалы с антибактериальной и антивирусной активностью
WO2010009075A1 (en) * 2008-07-14 2010-01-21 The University Of North Carolina At Chapel Hill Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
BRPI0507308A (pt) * 2004-01-29 2007-06-26 Baxter Int nanossuspensões de agentes anti-retrovirais para entrega ao sistema nervoso central aumentada
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20050048002A1 (en) * 2003-06-24 2005-03-03 Barrett Rabinow Method for delivering drugs to the brain
RU2008129083A (ru) * 2006-04-24 2010-01-20 Нм Тек Лтд. Наноматериалз Энд Микродевайсиз Текнолоджи (Gb) Функциональные наноматериалы с антибактериальной и антивирусной активностью
WO2010009075A1 (en) * 2008-07-14 2010-01-21 The University Of North Carolina At Chapel Hill Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds

Also Published As

Publication number Publication date
AU2011323458A1 (en) 2013-05-23
US20130236553A1 (en) 2013-09-12
CA2816123A1 (en) 2012-05-10
JP2013542945A (ja) 2013-11-28
EP2635260A4 (en) 2014-07-09
RU2013122656A (ru) 2014-12-10
WO2012061480A3 (en) 2013-01-03
AU2011323458B2 (en) 2017-02-23
EP2635260A2 (en) 2013-09-11
WO2012061480A2 (en) 2012-05-10
MX2013004981A (es) 2013-11-04

Similar Documents

Publication Publication Date Title
RU2632445C2 (ru) Композиции и способы доставки терапевтических средств
Puligujja et al. Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections
Gunaseelan et al. Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs
EP0871432B1 (en) Use of a composition containing polyether block copolymers
EP0839026B1 (en) Polyether block copolymer micellar compositions for targeting biological agents
Kovochich et al. Activation of latent HIV using drug-loaded nanoparticles
Ramana et al. Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs–modern Trojan horses to combat HIV
Haroun et al. Significant of injectable brucine PEGylated niosomes in treatment of MDA cancer cells
EP3474857A2 (en) Compositions and methods for the delivery of therapeutics
US20170165271A1 (en) Compositions and Methods for the Delivery of Therapeutics
US10022325B2 (en) Compositions and methods for the treatment of cancer
Guo et al. Rationally designed micellar nanocarriers for the delivery of hydrophilic methotrexate in Psoriasis treatment
Li et al. Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy
Sriraman et al. Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro
Senkiv et al. Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/phospholipidic nanocarriers of doxorubicin
Cao et al. Core-shell nanoparticles for targeted and combination antiretroviral activity in gut-homing T cells
US20160136105A1 (en) Compositions and Methods for the Delivery of Therapeutics
Levy et al. Reversible inhibition of efflux transporters by hydrogel microdevices
US8361510B2 (en) Nanogels for cellular delivery of therapeutics
Jaimalai et al. Drug delivery system targeting CD4+ T Cells for HIV-1 latency reactivation towards the viral eradication
US11458136B2 (en) Antiviral prodrugs and formulations thereof
Zhou et al. Extracellular vesicle-liposome-darunavir formulation for the treatment of HIV neuropathogenesis
US20230190663A1 (en) Prussian blue nanoparticles functionalization with latency reversing agents and broadly neutralizing antibodies, and applications thereof
Yao et al. A triple combination strategy for nasopharyngeal carcinoma: Aptamer-guided liposomal chemotherapy, engineered NK cells, and Fc-enhanced PD-L1 antibody therapy
WO2026026701A1 (zh) 非洛地平脂质体及其制备和应用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20191103